Article
Santa Barbara, CA-Miravant Medical Technologies will file its first new drug application for marketing approval of PhotoPoint SnET2, for the treatment of wet age-related macular degeneration (AMD).
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.